Mr. Elam has been founding, managing and advising healthcare and technology companies for more than 30 years.

Prior to founding Rezolute, Mr. Elam held various senior leadership positions in the industry including Senior Vice President at Nektar Therapeutics (NASDAQ: NKTR) where he ran the Pulmonary Business Unit and was instrumental in streamlining the organization and reshaping its pipeline. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Aerogen in Ireland and Pearl Therapeutics, which was acquired by AstraZeneca for $1 billion. Mr. Elam also played a fundamental role in launching Savara, Inc. (NASDAQ: SVRA) where he helped shape the company’s direction and path forward with his rare disease and pulmonary expertise. Mr. Elam also was the Co-Founder and Chief Financial Officer of e2open (NYSE: ETWO), a web-based supply chain platform company serving various industries including healthcare. Early in his career, Mr. Elam was a corporate partner at the law firm of Wilson Sonsini Goodrich & Rosati, where he advised both emerging growth companies and mature corporations such as Genentech and Hewlett Packard, and negotiated several notable deals, including the sale of Steve Jobs’ company, Next, to Apple.

Throughout his career, Mr. Elam has served on the board of directors of various healthcare companies in the US, Europe and Asia. He currently serves on the board of Rezolute and Savara.

Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.

Prior to joining Rezolute in 2017 as a founding member of the management team, Dr. Roberts directed clinical development at Fibrogen, Inc., where he helped successfully launch and execute the global Phase 3 program and pharmaceutical partnership for a novel oral therapy for anemia associated with kidney disease, concluding the largest Phase 3 program ever conducted in CKD anemia, and resulting in global NDA filings and approvals. During Dr. Roberts’ tenure, Fibrogen achieved the largest biotech IPO in the previous 10 years.

From 2007 until 2012 Dr. Roberts held clinical development positions of increasing responsibility at Cymabay, Inc., where he developed novel therapies for metabolic diseases such as diabetes, dyslipidemia, NASH, and gout. His program and clinical leadership from IND through clinical proof-of-concept helped secure a global licensing and co-development agreement with a major pharmaceutical partner for a novel diabetes therapy, as well as the successful filing of a NDA for Seladelpar.

He is an inventor or author on more than 25 patents and publications in the fields of Endocrinology and Metabolism. Dr. Roberts received his B.S. in biochemistry from the University of California, San Diego and his M.D. Magna Cum Laude from Georgetown University. He completed a residency in Internal Medicine and a fellowship in Endocrinology at Stanford University Medical Center, where he also now serves as an Adjunct Associate Professor in the Division of Endocrinology.

Ms. Stewart has more than 30 years of experience in biopharmaceutical regulatory affairs and quality assurance, overseeing and developing innovative regulatory strategies and leading interactions with global health authorities for drugs and biologics aimed at addressing unmet medical needs. In addition to being an independent regulatory consultant for several years, she is chief regulatory officer for Candel Therapeutics and previously was CRO at Frequency Therapeutics and Kaleido Biosciences. Prior to that, she was senior vice president of regulatory affairs, quality and compliance at Tokai Pharmaceuticals and vice president, regulatory affairs at Transmolecular Therapeutics. She also spent 13 years at Genzyme Corporation (Sanofi) in regulatory and compliance roles, including serving as vice president, regulatory affairs, after beginning her career with Abbott Laboratories in regulatory and quality positions. She is the regulatory advisor for The Termeer Foundation.

Ms. Stewart received her J.D. from Concord Law School at Purdue University Global, her LL.M from the Maurice A. Deane School of Law, Hofstra University, and her B.A. from the University of Massachusetts. She is a Fellow of the Regulatory Affairs Professionals Society and holds both US and EU RAC certifications.

Mr. Evans has over 15 years of experience leading public and private life science companies through financial operations, investor relations, and business development activities.

Prior to joining Rezolute, he served as Chief Executive Officer of AlloRock, Inc., a biotechnology company in the cardiometabolic disease space, as well as Chief Executive Officer of Specialty Renal Products, Inc., a medical device company in the dialysis space. Previously, Mr. Evans served as Chief Executive Officer of Nephros, Inc. (Nasdaq:NEPH), and Chief Financial Officer of Nile Therapeutics, Inc. (Nasdaq:NLTX). Since 2015, Mr. Evans has been Managing Director of PoC Capital, LLC, a fund focused on investing in public life science companies.

He holds a Bachelor of Science in Chemical Engineering from Rice University, a Master of Science in Biomedical Engineering from a joint program at the University of Texas at Arlington and Southwestern Medical School, and a Master of Business Administration from the Fuqua School of Business at Duke University.

Mr. Karnawat has over 25 years of experience in global commercialization of biopharmaceuticals and medical devices. He has launched products across multiple disease states, including ultra-rare bone and metabolic diseases, diabetes, obesity, and rheumatoid arthritis. Before joining the Company, Mr. Karnawat served as a Vice President at Cytokinetics and Ultragenyx. At Ultragenyx, he was responsible for leading key commercial functions in launching four ultra-rare disease products, including Crysvita with indications for X-linked Hypophosphatemia and Tumor-induced Osteomalacia. Before that, he led the Market Access teams at Myriad Genetics and Vivus Pharmaceuticals. At Novo Nordisk, Mr. Karnawat led Analytics and Commercial Operations teams to support the US launch of Victoza. He was a Field Sales Leader at LifeScan, a Johnson & Johnson franchise, for blood glucose monitors. Mr. Karnawat started his career at Deloitte Consulting. His education includes an MBA from the Wharton School of Business at the University of Pennsylvania, a Ph.D. and an M.S. in Engineering from North Dakota State University, and a B.E. in Civil Engineering from the College of Engineering in Pune, India.

Mr. Deperro has over 25 years of experience in public and private life science companies. As a founding management team member at Rezolute (NASDAQ: RZLT), he serves as Senior Vice President & Head of Operations while maintaining his long-term role as Head of Technical Operations.

Prior to joining Rezolute, Mr. Deperro served as Vice President and General Manager at AntriaBio, led CDMO manufacturing operations at Agere Pharmaceuticals and Bend Research Inc., as well as Commercial and Clinical Manufacture at Alkermes Inc.

He holds a Bachelor of Science in Mechanical Engineering from the University of Notre Dame and was a commissioned officer in the US Army.

With a passion for both people and science, Ms. Quinn brings over 20 years of experience in human resources management to Rezolute. As the Sr. Director of People and Culture, she has been instrumental in the successful growth of the company thus far and is responsible for ensuring that our people processes and culture scale well as we continue to grow. Through her leadership, Ms. Quinn continues to elevate the role of HR as a strategic partner in driving organizational excellence in the fast-paced and dynamic biotech industry. Prior to joining Rezolute, she held HR roles of progressive responsibility within the technology and medical industries.

Ms. Baglaneas has more than a decade of experience in corporate communications, investor relations and public relations in the healthcare industry, partnering with executive leadership teams to develop and execute on strategic communications plans for companies of all sizes and stages. Prior to joining Rezolute, she led the corporate communications and investor relations function at Theseus Pharmaceuticals, a targeted oncology biopharmaceutical company, working with leadership to expand investor base and craft corporate and program-specific messaging through IPO and clinical data readouts. Prior to Theseus, Ms. Baglaneasserved in roles of increasing responsibility spearheading investor relations and corporate communications strategy for biotech companies, leading the PR efforts for the life sciences and corporate transactions practice groups of global law firm, Morgan Lewis, and managed the PR for a Congressional campaign in Massachusetts.

She holds a B.A. in English Literature and Art History from Providence College.